November 8, 2026

Newsletter

The European Post

Policy • Diplomacy • strategic insight

LATEST
Israeli Settlement Imports Ban Splits Commission And CouncilUnlimited Pesticide Approvals Face Public Rejection In PollMethane Import Rules Delayed A Year With Review ClauseSustainable Tourism Strategy Hands Europe A Toolbox For Crowded CitiesPharma Package Heads To Parliament After Council Backs Drug ReformRussia Sanctions Alignment Pulls Nine Partners Into Arms ListingsBrazil Farm Exports Jump 14.8 Percent Under EU Mercosur Trade DealNorth Korea IT Workers Draw Joint Western Sanctions ResponseDRC Sanctions Regime Gains Arms Ban And Peacekeeper ProtectionMade With Taiwan Pitch Tests Europe’s Economic Security AppetiteGeorgia Visa-Free Regime Faces January Review After Kallas WarningTeacher Shortages Put The EU Teachers Agenda To The TestKingspan Fine And KKR Charge Put EU Merger Control To WorkMEPs Near First Vote On EU Space Act In Parliament Industry CommitteeMercosur Safeguard Rules Let EU Curb Surges In Car And Goods ImportsMontenegro And Albania Receive EU Accession Roadmaps From CommissionHelsinki Presses Washington Over Paid-For Patriot InterceptorsMeloni Letter Exposes The EU Single Voice Problem On UkraineEmissions Trading Link Defines The EU-UK Summit Agenda For 20 NovemberAddis Ababa Talks Test The EU-African Union Partnership PlanIsraeli Settlement Imports Ban Splits Commission And CouncilUnlimited Pesticide Approvals Face Public Rejection In PollMethane Import Rules Delayed A Year With Review ClauseSustainable Tourism Strategy Hands Europe A Toolbox For Crowded CitiesPharma Package Heads To Parliament After Council Backs Drug ReformRussia Sanctions Alignment Pulls Nine Partners Into Arms ListingsBrazil Farm Exports Jump 14.8 Percent Under EU Mercosur Trade DealNorth Korea IT Workers Draw Joint Western Sanctions ResponseDRC Sanctions Regime Gains Arms Ban And Peacekeeper ProtectionMade With Taiwan Pitch Tests Europe’s Economic Security AppetiteGeorgia Visa-Free Regime Faces January Review After Kallas WarningTeacher Shortages Put The EU Teachers Agenda To The TestKingspan Fine And KKR Charge Put EU Merger Control To WorkMEPs Near First Vote On EU Space Act In Parliament Industry CommitteeMercosur Safeguard Rules Let EU Curb Surges In Car And Goods ImportsMontenegro And Albania Receive EU Accession Roadmaps From CommissionHelsinki Presses Washington Over Paid-For Patriot InterceptorsMeloni Letter Exposes The EU Single Voice Problem On UkraineEmissions Trading Link Defines The EU-UK Summit Agenda For 20 NovemberAddis Ababa Talks Test The EU-African Union Partnership Plan
November 8, 2026

Newsletter

The European Post

Policy • Diplomacy • strategic insight

LATEST
Israeli Settlement Imports Ban Splits Commission And CouncilUnlimited Pesticide Approvals Face Public Rejection In PollMethane Import Rules Delayed A Year With Review ClauseSustainable Tourism Strategy Hands Europe A Toolbox For Crowded CitiesPharma Package Heads To Parliament After Council Backs Drug ReformRussia Sanctions Alignment Pulls Nine Partners Into Arms ListingsBrazil Farm Exports Jump 14.8 Percent Under EU Mercosur Trade DealNorth Korea IT Workers Draw Joint Western Sanctions ResponseDRC Sanctions Regime Gains Arms Ban And Peacekeeper ProtectionMade With Taiwan Pitch Tests Europe’s Economic Security AppetiteGeorgia Visa-Free Regime Faces January Review After Kallas WarningTeacher Shortages Put The EU Teachers Agenda To The TestKingspan Fine And KKR Charge Put EU Merger Control To WorkMEPs Near First Vote On EU Space Act In Parliament Industry CommitteeMercosur Safeguard Rules Let EU Curb Surges In Car And Goods ImportsMontenegro And Albania Receive EU Accession Roadmaps From CommissionHelsinki Presses Washington Over Paid-For Patriot InterceptorsMeloni Letter Exposes The EU Single Voice Problem On UkraineEmissions Trading Link Defines The EU-UK Summit Agenda For 20 NovemberAddis Ababa Talks Test The EU-African Union Partnership PlanIsraeli Settlement Imports Ban Splits Commission And CouncilUnlimited Pesticide Approvals Face Public Rejection In PollMethane Import Rules Delayed A Year With Review ClauseSustainable Tourism Strategy Hands Europe A Toolbox For Crowded CitiesPharma Package Heads To Parliament After Council Backs Drug ReformRussia Sanctions Alignment Pulls Nine Partners Into Arms ListingsBrazil Farm Exports Jump 14.8 Percent Under EU Mercosur Trade DealNorth Korea IT Workers Draw Joint Western Sanctions ResponseDRC Sanctions Regime Gains Arms Ban And Peacekeeper ProtectionMade With Taiwan Pitch Tests Europe’s Economic Security AppetiteGeorgia Visa-Free Regime Faces January Review After Kallas WarningTeacher Shortages Put The EU Teachers Agenda To The TestKingspan Fine And KKR Charge Put EU Merger Control To WorkMEPs Near First Vote On EU Space Act In Parliament Industry CommitteeMercosur Safeguard Rules Let EU Curb Surges In Car And Goods ImportsMontenegro And Albania Receive EU Accession Roadmaps From CommissionHelsinki Presses Washington Over Paid-For Patriot InterceptorsMeloni Letter Exposes The EU Single Voice Problem On UkraineEmissions Trading Link Defines The EU-UK Summit Agenda For 20 NovemberAddis Ababa Talks Test The EU-African Union Partnership Plan

Pharma Package Heads To Parliament After Council Backs Drug Reform

Shani Tarashaj
National Bureau Chief, Health and Wellbeing

Brussels: The EU pharma package moved a step closer to law on 28 September 2026, when the Council of the EU adopted the reform and left the European Parliament to deliver the final vote. The text rewrites the bloc’s medicines rules for the first time in two decades, and it will decide how long drugmakers keep their market edge in all 27 member states.

The Commission proposed the pharmaceutical strategy for Europe reforms in April 2023, and negotiators needed more than three years to close the file. The Council press release presents the pharma package as a bid to make medicines more accessible and the sector more competitive. Both aims pull in different directions, and the compromise shows it.

Regulatory data protection sits at the centre of the pharma package. Innovators receive eight years of data protection and one year of market protection, and they can earn up to two further years if they meet conditions on trials, launch in several member states or address an unmet medical need. The total normally stops at 11 years, or 12 with a transferable exclusivity voucher. Orphan medicines receive nine years of market exclusivity, with up to 11 years for breakthrough products.

The voucher is the most contested tool in the pharma package. Developers of priority antimicrobials can earn one extra year of protection, which they can attach to another product. Lawmakers added a ceiling, so a company cannot use the voucher on a product whose annual EU gross sales exceeded 490 million euros over the previous four years. That limit tries to reward work on drug-resistant infections without handing a windfall to blockbuster brands.

Generic and biosimilar makers also gain from the pharma package. The reform widens the Bolar exemption, which lets them run studies and prepare tenders before the originator’s protection expires, and it cuts the European Medicines Agency’s assessment time from 210 to 180 days, with 150 days on the accelerated pathway. Faster reviews matter for patients, because a medicine that wins approval still needs national pricing decisions before it reaches a pharmacy.

Supply is the other pressure point. Member states may require companies that hold protection to supply enough product to meet national patient needs, and the text includes safeguards so governments cannot use that power mainly to support parallel trade. This rule overlaps with the separate Critical Medicines Act, which deals with shortages and supply resilience, so negotiators will have to keep the two files consistent.

What happens next depends on Parliament. Once MEPs adopt the regulation and the directive and the texts appear in the Official Journal, the rules enter into force, and member states will have two years to transpose the directive, with some exceptions. Companies, patient groups and health ministries should use that window to plan, because the pharma package changes launch strategies, pricing talks and generic entry dates across the single market. Until the plenary vote happens, the reform stays unfinished.

Comments